Physician profile
Swati Kumar
NPI 1821478496
$3,472.50
in general payments reported to CMS, 2019-2025
32 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.39 · 2022: $281 · 2023: $696 · 2024: $855 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,122.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $750.23 | 2022-2025 | Evenity, Repatha, Prolia |
| Novartis Pharmaceuticals Corporation | $511.42 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.36 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $192.78 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $185.70 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $182.85 | 2023-2025 | Farxiga |
| Lilly USA, LLC | $144.60 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $121.84 | 2024-2025 | Camzyos, Eliquis |
| Xeris Pharmaceuticals, INC. | $121.80 | 2022-2025 | Recorlev |
| Esperion Therapeutics, INC. | $85.67 | 2025 | Nexletol |
| Abiomed | $74.58 | 2025 | |
| Novo Nordisk INC | $72.58 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Inspire Medical Systems, INC. | $71.09 | 2025 | Inspire |
| Medtronic, INC. | $60.76 | 2022-2024 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Radius Health, INC. | $58.52 | 2024-2025 | Tymlos |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $57.63 | 2022-2023 | Verquvo |
| Scpharmaceuticals INC. | $50.97 | 2025 | |
| Alnylam Pharmaceuticals INC. | $49.99 | 2025 | Amvuttra |
| Dexcom, INC. | $49.43 | 2022-2024 | Dexcom G6 Transmitter |
| Tolmar, INC. | $46.27 | 2025 | Jatenzo |
| Lexicon Pharmaceuticals, INC. | $44.92 | 2024 | |
| Pfizer INC. | $42.18 | 2023 | |
| Edwards Lifesciences Corporation | $39.99 | 2025 | Sapien 3 Ultra Resilia |
| Cequr Corporation | $38.00 | 2025 | Cequr Simplicity |
| Heartflow, INC. | $29.57 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $25.34 | 2025 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $23.70 | 2024 | Arcalyst |
| Abbott Laboratories | $22.17 | 2022 | |
| Bracco Diagnostics INC. | $20.98 | 2025 | |
| Agios Pharmaceuticals, INC. | $20.67 | 2025 | Pyrukynd |
| Recordati_rare_diseases_inc. | $15.78 | 2025 | Isturisa |
| Echosens North America, INC. | $14.13 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swati Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.